PepGen (PEPG) Sets $125M Share Sale at $5.00 Each
Biotech PepGen (PEPG) is selling 25M shares at $5.00 for expected gross proceeds of $125M before costs, according to TradingView citing BusinessWire.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
PepGen has priced 25 million shares at $5.00 each, with expected gross proceeds of $125 million before offering expenses.
Underwriters hold a 30-day option to buy up to 3.75 million more shares. Closing is anticipated on or about November 13, 2026, subject to customary conditions.
The company intends to use the money for clinical development and working capital, without a specific allocation by program. The release gave no prior-period comparison. Details come from TradingView, which relays a BusinessWire press release.
why it matters
This is a financing rather than a clinical update. For investors, the key effect is dilution: more shares outstanding, with proceeds reported before costs. The final net amount and any exercise of the underwriters' option will show the real size of the raise.
tags
instruments
sources
- PepGen (PEPG) Prices $125M Offering at $5.00 per Share — TradingView, 12 November 2026 at 03:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗